IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
Last trade$27.45
Day change-$2.91 (-9.58%)
Day range$26.70 – $31.91
Volume1,493,267
Market cap$2.94B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$2.94B
Price / earnings
—
Price / book
2.69×
Price / sales
80.35×
EV / sales
73.2×
EV / EBITDA
-5.81×
Profitability
Earnings per share
-$4.34
Return on assets
-34.54%
Return on equity
-38.46%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
9.04×
Quick ratio
9.04×
Cash ratio
2.71×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$349.8M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for IDYA, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$10.24M
$8.86M
$6.56M
$10.88M
$207.83M
$0
$0
$7M
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$10.24M
$8.86M
$6.56M
$10.88M
$207.83M
$0
$0
$7M
Selling, general and administrative
$26.3M
$22.46M
$19.38M
$18.85M
$16.39M
$14.58M
$13.5M
$10.96M
Research and development
$121.58M
$108.69M
$95.73M
$86.6M
$82.99M
$74.23M
$70.89M
$140.18M
Total operating expenses
$147.87M
$131.15M
$115.1M
$105.45M
$99.38M
$88.81M
$84.39M
$151.14M
Operating income
-$137.63M
-$122.29M
-$108.54M
-$94.57M
$108.45M
-$88.81M
-$84.39M
-$144.14M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$125.75M
-$112.45M
-$98.54M
-$83.27M
$119.24M
-$77.49M
-$72.18M
-$130.31M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$125.75M
-$112.45M
-$98.54M
-$83.27M
$119.24M
-$77.49M
-$72.18M
-$130.31M
Net income attributable to common shareholders
-$125.75M
-$112.45M
-$98.54M
-$83.27M
$119.24M
-$77.49M
-$72.18M
-$130.31M
EBITDA
-$137.02M
-$121.6M
-$107.86M
-$93.85M
$109.11M
-$88.09M
-$83.79M
-$143.57M
Basic earnings per share
-$1.22
-$1.22
-$1.11
-$0.94
$1.35
-$0.88
-$0.82
-$1.49
Diluted earnings per share
-$1.22
-$1.22
-$1.11
-$0.95
$1.33
-$0.88
-$0.82
-$1.49
Recent news
Company coverage with links to the original publishers.
IDEAYA Biosciences reported a Q3 loss of $1.22 per share, beating the consensus estimate of $1.26 loss by 3.18%. The company posted revenues of $10.24 million, surpassing consensus by 14.69%, though this represents a significant decline from $207.83 million in the year-ago quarter. The stock has underperformed the S&P 500 by 18.7% year-to-date and carries a Zacks Rank #3 (Hold) rating.
Acadia Pharmaceuticals is expected to report Q3 2026 earnings of $0.21 per share, representing a 19.2% year-over-year decline, despite revenues rising 20.2% to $334.87 million. With a negative Earnings ESP of -0.59% and Zacks Rank #3, the company is not considered a compelling earnings-beat candidate. However, Acadia has beaten consensus EPS estimates in 3 of the last 4 quarters, most recently delivering a +200% surprise.
IDEAYA Biosciences is expected to report a quarterly loss of $1.26 per share with revenues of $8.93 million for Q3 2026, representing significant year-over-year declines. However, the company has a positive Earnings ESP of +1.50% combined with a Zacks Rank #3 (Hold), suggesting it will likely beat consensus EPS estimates. The company has only beaten estimates once in the last four quarters.
IDEAYA Biosciences announced positive Phase 2/3 trial results for darovasertib combined with crizotinib in treating metastatic uveal melanoma. The combination showed a median progression-free survival of 6.9 months versus 3.1 months for standard therapy, with a 37.1% overall response rate compared to 5.8%. The company plans to submit an FDA New Drug Application in the second half of 2026. IDYA shares surged 26.36% in premarket trading.
The global antibody optimization service market is projected to grow from USD 2.77 billion in 2024 to USD 6.07 billion by 2034, driven by advances in gene-editing technologies, AI/computational tools, and increasing biologics R&D.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.